Alzheimer's Disease therapy with antibody against oligomeric Abeta peptides
A novel, proprietary antibody for the therapy and/or diagnosis of Alzheimer's Disease (AD) was developed by scientists at the University Medical Center Göttingen. This antibody targets specifically only oligomeric Amyloid beta peptides.
Further Information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-151
Contact
Dr. Jens-Peter Horst
